Published in Nat Nanotechnol on October 24, 2010
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat Chem (2012) 1.23
Scaling behaviour for the water transport in nanoconfined geometries. Nat Commun (2014) 1.20
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Physicochemical characterization, and relaxometry studies of micro-graphite oxide, graphene nanoplatelets, and nanoribbons. PLoS One (2012) 1.08
In vivo magnetic resonance imaging of hyperpolarized silicon particles. Nat Nanotechnol (2013) 1.08
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Controlled intracellular self-assembly of gadolinium nanoparticles as smart molecular MR contrast agents. Sci Rep (2013) 1.03
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02
Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent. Int J Nanomedicine (2013) 1.00
High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano (2013) 0.98
Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology (2013) 0.97
Theranostic mesoporous silica nanoparticles biodegrade after pro-survival drug delivery and ultrasound/magnetic resonance imaging of stem cells. Theranostics (2015) 0.95
Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95
Synthesis of long T₁ silicon nanoparticles for hyperpolarized ²⁹Si magnetic resonance imaging. ACS Nano (2013) 0.94
In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine (Lond) (2012) 0.93
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Degradation and biocompatibility of multistage nanovectors in physiological systems. J Biomed Mater Res A (2013) 0.90
Location-tuned relaxivity in Gd-doped mesoporous silica nanoparticles. J Mater Chem (2012) 0.88
Cytotoxicity, cytocompatibility, cell-labeling efficiency, and in vitro cellular magnetic resonance imaging of gadolinium-catalyzed single-walled carbon nanotubes. J Biomed Mater Res A (2013) 0.88
Evaluation of cell function upon nanovector internalization. Small (2012) 0.87
Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol (2014) 0.86
Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials (2013) 0.85
Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Lett (2014) 0.85
Ultrahigh relaxivity and safe probes of manganese oxide nanoparticles for in vivo imaging. Sci Rep (2013) 0.85
Gadolinium-conjugated gold nanoshells for multimodal diagnostic imaging and photothermal cancer therapy. Small (2013) 0.85
Environmentally responsive MRI contrast agents. Chem Commun (Camb) (2013) 0.85
Silica microparticles as a solid support for gadolinium phosphonate magnetic resonance imaging contrast agents. J Am Chem Soc (2012) 0.85
Multistage vector (MSV) therapeutics. J Control Release (2015) 0.84
Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc Natl Acad Sci U S A (2015) 0.84
Synthesis, Characterization, In Vitro Phantom Imaging, and Cytotoxicity of A Novel Graphene-Based Multimodal Magnetic Resonance Imaging - X-Ray Computed Tomography Contrast Agent. J Mater Chem B Mater Biol Med (2014) 0.84
A Microfluidic Platform to design crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for enhanced MRI. Sci Rep (2016) 0.83
Impact of biopolymer matrices on relaxometric properties of contrast agents. Interface Focus (2016) 0.83
The magnetic, relaxometric, and optical properties of gadolinium-catalyzed single walled carbon nanotubes. J Appl Phys (2013) 0.83
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. Biomaterials (2014) 0.82
Interplay between longitudinal and transverse contrasts in Fe3O4 nanoplates with (111) exposed surfaces. ACS Nano (2014) 0.82
Hierarchically-Structured Magnetic Nanoconstructs with Enhanced Relaxivity and Cooperative Tumor Accumulation. Adv Funct Mater (2014) 0.81
Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.80
High signal contrast gating with biomodified Gd doped mesoporous nanoparticles. Chem Commun (Camb) (2012) 0.80
Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines. Med Sci (Basel) (2014) 0.80
Bacteriophage Associated Silicon Particles: Design and Characterization of a Novel Theranostic Vector with Improved Payload Carrying Potential. J Mater Chem B Mater Biol Med (2013) 0.80
Opportunities for NanoTheranosis in Lung Cancer and Pulmonary Metastasis. Clin Transl Imaging (2014) 0.79
MRI biosensors: a short primer. J Magn Reson Imaging (2013) 0.79
Water transport control in carbon nanotube arrays. Nanoscale Res Lett (2014) 0.79
Porous silicon microparticles for delivery of siRNA therapeutics. J Vis Exp (2015) 0.78
New clathrin-based nanoplatforms for magnetic resonance imaging. PLoS One (2012) 0.78
Toxicity evaluation of Gd2O3@SiO2 nanoparticles prepared by laser ablation in liquid as MRI contrast agents in vivo. Int J Nanomedicine (2014) 0.78
Cellular uptake and imaging studies of glycosylated silica nanoprobe (GSN) in human colon adenocarcinoma (HT 29 cell line). Int J Nanomedicine (2013) 0.78
Facile non-hydrothermal synthesis of oligosaccharides coated sub-5 nm magnetic iron oxide nanoparticles with dual MRI contrast enhancement effect. J Mater Chem B Mater Biol Med (2014) 0.77
Towards An Advanced Graphene-Based Magnetic Resonance Imaging Contrast Agent: Sub-acute Toxicity and Efficacy Studies in Small Animals. Sci Rep (2015) 0.77
Porphyrin-substituted H-NOX proteins as high-relaxivity MRI contrast agents. Inorg Chem (2013) 0.77
Functional nanoparticles for magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.77
Design of nanovectors for therapy and imaging of cardiovascular diseases. Methodist Debakey Cardiovasc J (2012) 0.77
Current applications of graphene oxide in nanomedicine. Int J Nanomedicine (2015) 0.75
Shape-Dependent Relaxivity of Nanoparticle-Based T1 Magnetic Resonance Imaging Contrast Agents. J Phys Chem C Nanomater Interfaces (2016) 0.75
Nanomedicines for kidney diseases. Kidney Int (2016) 0.75
Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities. Graphene Technol (2016) 0.75
Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res (2016) 0.75
A Bayesian hierarchical model for maximizing the vascular adhesion of nanoparticles. Comput Mech (2014) 0.75
The Emerging Role of Nanotechnology in Cell and Organ Transplantation. Transplantation (2016) 0.75
Patient-specific computational modeling and magnetic nanoconstructs: tools for maximizing the efficacy of stem cell-based therapies. Methodist Debakey Cardiovasc J (2013) 0.75
Water bridge coordination on the metal-rich facets of Gd2O3 nanoplates confers high T1 relaxivity. Nanoscale (2016) 0.75
Acute Toxicity Evaluation of Glycosylated Gd(3+)-Based Silica Nanoprobe. Mol Imaging Biol (2016) 0.75
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev (1999) 12.52
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev (2008) 3.80
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev (2008) 3.43
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release (2009) 3.08
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials (2006) 2.71
Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J Am Chem Soc (2005) 2.15
Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb) (2005) 2.05
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging (2006) 1.97
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Snapshot magnetic resonance imaging (Nobel lecture). Angew Chem Int Ed Engl (2004) 1.33
Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano Lett (2008) 1.31
Can receptors be imaged with MRI agents? Q J Nucl Med (1997) 1.30
Rational design of protein-based MRI contrast agents. J Am Chem Soc (2008) 1.28
Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA (2005) 1.22
Noncovalent functionalization of carbon nanotubes with amphiphilic gd3+ chelates: toward powerful t1 and t2 MRI contrast agents. Nano Lett (2007) 1.17
Destroying gadofullerene aggregates by salt addition in aqueous solution of Gd@C(60)(OH)(x) and Gd@C(60)[C(COOH(2))](10). J Am Chem Soc (2005) 1.11
Phosphinic derivative of DTPA conjugated to a G5 PAMAM dendrimer: an 17O and 1H relaxation study of its Gd(III) complex. Dalton Trans (2006) 0.97
Maximizing the relaxivity of HSA-bound gadolinium complexes by simultaneous optimization of rotation and water exchange. Chem Commun (Camb) (2007) 0.94
Multistage Mesoporous Silicon-based Nanocarriers: Biocompatibility with Immune Cells and Controlled Degradation in Physiological Fluids. Controll Release Newsl (2008) 0.93
General treatment of paramagnetic relaxation enhancement associated with translational diffusion. J Chem Phys (2009) 0.87
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J Am Chem Soc (2005) 2.15
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Fabrication of porous ultra-short single-walled carbon nanotube nanocomposite scaffolds for bone tissue engineering. Biomaterials (2007) 1.67
Normal values for renal length and volume as measured by magnetic resonance imaging. Clin J Am Soc Nephrol (2006) 1.67
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation (2009) 1.61
First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc (2003) 1.59
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
In vivo behavior of large doses of ultrashort and full-length single-walled carbon nanotubes after oral and intraperitoneal administration to Swiss mice. ACS Nano (2010) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
Biventricular takotsubo cardiomyopathy: cardiac magnetic resonance imaging as useful diagnostic tool. Tex Heart Inst J (2011) 1.43
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Assessing myocardial viability and infarct transmurality with left ventricular electromechanical mapping in patients with stable coronary artery disease: validation by delayed-enhancement magnetic resonance imaging. Circulation (2002) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
In vivo biocompatibility of ultra-short single-walled carbon nanotube/biodegradable polymer nanocomposites for bone tissue engineering. Bone (2008) 1.35
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano Lett (2008) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Stability of antibody-conjugated gold nanoparticles in the endolysosomal nanoenvironment: implications for noninvasive radiofrequency-based cancer therapy. Nanomedicine (2012) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc (2005) 1.23
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai) (2008) 1.23
Detecting and treating cancer with nanotechnology. Mol Diagn Ther (2008) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16